



March 25, 2019

Company Name:  **TAIYO HOLDINGS CO., LTD.**
 Representative: Eiji Sato, President and CEO
 (Code: 4626, Listed on First Section of Tokyo Stock Exchange)
 Contact: Shuichi Omi, Managing Executive Officer,
 Global Chief of Finance & Accounting
 Tel: 03-5953-5200 (main line)

Notification of the Acquisition of a Long-listed Product

TAIYO HOLDINGS CO., LTD. (hereinafter “Taiyo Holdings”) announces that we have today come to an agreement and entered into an asset transfer contract with Nippon Boehringer Ingelheim Co., Ltd. (hereinafter “NBI”) for our subsidiary TAIYO Pharma Co., Ltd. (hereinafter “Taiyo Pharma”) to acquire the approval for manufacture and sale and the manufacture and sales rights from NBI for the long-listed product of Mexitil® that is currently manufactured and sold in Japan by NBI (hereinafter “the Acquisition”).

1. Reasons for the Acquisition

Taiyo Holdings is making various efforts to grow our medical and pharmaceutical business into a business that will serve as the second pillar of our company as stated in our medium-term business plan NEXT STAGE 2020. As a part of that, we are acquiring long-listed products and beginning the pharmaceutical drugs manufacture and sales business with Taiyo Pharma.

Mexitil® is a socially important pharmaceutical drug with a long track record of use. In the future, Taiyo Pharma will strive to maintain the product quality and collect information (e.g., safety information) by establishing points of contact with medical institutions and patients through the stable supply of Mexitil®. At the same time, we are aiming to build a stable and continuous business through optimization of information provision activities and other business activities by expanding our product lineup.

2. Overview of the Acquisition

(1) Assets in This Matter

This applies to all dosage forms of a long-listed product called Mexitil® for which NBI possesses the manufacture and sales rights in Japan and for which the company manufactures and sells.

	Product	Therapeutic Category
1	Mexitil®	Antiarrhythmic and diabetic neuropathic agent

(2) Date of Acquisition

March 28, 2019

(3) Timing of the Succession of the Approval for Manufacture and Sale

October 2019 (scheduled)

(4) Items of the Assets in This Matter

The inventory assets and intangible assets relating to this matter are scheduled to serve as the assets in this matter.

3. Future Forecasts

The impact on the consolidated financial results for the fiscal year ending March 31, 2019 of Taiyo Holdings from the Acquisition will be minor. However, we will provide immediate notification in the event of any matters requiring disclosure.

Overview of TAIYO HOLDINGS CO., LTD.

Taiyo Holdings is headquartered in Tokyo and is mainly engaged in business relating to the manufacture and sale of electronic parts and semiconductor chemicals including printed wiring board (PWB) materials. Our group has a top class share of the global market with solder resist that is essential for PWBs. Nevertheless, the aim of Taiyo Holdings is to break free from a business structure that relies heavily on the PWB materials business. Accordingly, we are working to make the leap to becoming a comprehensive chemical company focused on the keyword of the “chemicals” possessed by our group. We are creating new businesses in four fields – medical and pharmaceuticals, food and energy in addition to electronics (including solder resist) – as areas that are expected to grow in the future.

Please visit <http://www.taiyo-hd.co.jp/en/> for more details about Taiyo Holdings.

Overview of TAIYO Pharma Co., Ltd.

We established Taiyo Pharma as a wholly owned subsidiary of Taiyo Holdings on August 2, 2017. We would like the company to contribute to society through the development and expansion of the medical and pharmaceutical drugs business with a focus on the manufacture and sale of long-listed products.

Please visit <https://www.taiyo-pharma.co.jp/> for more details about Taiyo Pharma.

Boehringer Ingelheim

Improving the health and quality of life of patients is the goal of the research-driven pharmaceutical company Boehringer Ingelheim. The focus in doing so is on diseases for which no satisfactory treatment option exists to date. The company therefore concentrates on developing innovative therapies that can extend patients' lives. In animal health, Boehringer Ingelheim stands for advanced prevention.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the pharmaceutical industry's top 20 companies. Some 50,000 employees create value through innovation daily for the three business areas human pharmaceuticals, animal health and biopharmaceuticals. In 2017, Boehringer Ingelheim achieved net sales of nearly 18.1 billion euros. R&D expenditure, exceeding three billion euros, corresponded to 17.0 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success, rather than short-term profit. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

For more information:-

Boehringer Ingelheim

<http://www.boehringer-ingelheim.com/>

Boehringer Ingelheim Japan

<http://www.boehringer-ingelheim.jp/>